Genotypic and phenotypic resistance of Mycobacterium tuberculosis to rifamycins and fluoroquinolones [1]

International Journal of Tuberculosis and Lung Disease

Volumn 6, Issue 10, 2002, Pages 936-937

  Yew, W W ^a   Chan, E ^a   Chan, C Y ^a   Cheng, A F ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAMYCIN; SITAFLOXACIN; SPARFLOXACIN;

ANTIBIOTIC RESISTANCE; BACTERIAL GENE; CODON; GENE MUTATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; LETTER; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENOTYPE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; RIFAMPIN;

EID: 0036799416     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Torres M J, Criado A, Gonzalez N, Palomares J C, Aznar J. Rifampin and isoniazid resistance associated mutations in Mycobacterium tuberculosis clinical isolates in Seville, Spain. Int J Tuberc Lung Dis 2002; 6: 160-163.
2. Uzun M, Erturan Z, Ang O. Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis 2002; 6: 164-165.
3. Park Y K, Kim B J, Ryu S, et al. Cross-resistance between rifampicin and KRM-1648 is associated with specific rpoB alleles in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2002; 6: 166-170.
4. O'Brien R J, Lyle M A, Snider D E Jr. Rifabutin (ansamycin LM427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. Rev Infect Dis 1987; 9: 519-530.
5. Hong Kong Chest Service/British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis 1992; 73: 59-67.
6. Bodmer T, Zurcher G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicinresistant Mycobacterium tuberculosis. J Antimicrob Chemother 1995; 35: 345-348.
7. Yang B, Koga H, Ohno H, et al. Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother 1998; 42: 621-628.
8. Takiff H, Salazar L, Guerrero C, et al. Cloning and nucleotide sequence of the Mycobacterium tuberculosis gyrA and gyrB genes, and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38: 773-780.
9. Alangaden G J, Manavathu E K, Vakulenko S B, Zvonok N M, Lerner S A. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-1703.
10. Sullivan E A, Kreiswirth B N, Palumbo L, et al. Emergence of fluoquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-1150.
11. Kocagoz T, Hackbarth C J, Unsal I, Rosenberg E Y, Nikaido H, Chambers H F. Gyrase mutations in laboratory-selected fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-1774.
12. Xu C, Kreiswirth B N, Sreevatsan S, Musser J M, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J Infect Dis 1996; 174: 1127-1130.
13. Perlman D C, El Sadr W M, Heifers L B, et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 1997; 11: 1473-1478.